AU Patent

AU2020209216A1 — PCSK9 inhibitors and methods of use thereof

Assigned to AstraZeneca AB · Expires 2021-08-26 · 5y expired

What this patent protects

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.

USPTO Abstract

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020209216A1
Jurisdiction
AU
Classification
—
Expires
2021-08-26
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.